Patrick Carroll, the Chief Medical Officer of Hims & Hers Health Inc (HIMS, Financial), has sold 20,000 shares of the company on February 28, 2024, according to a recent SEC Filing. The transaction was executed at a stock price of $13.19 per share, resulting in a total sale amount of $263,800.
Hims & Hers Health Inc (HIMS, Financial) is a telehealth company that provides modern personalized health and wellness experiences to consumers. The company operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to primary care, mental health, sexual health, dermatology, and more.
Over the past year, the insider, Patrick Carroll, has sold a total of 20,000 shares and has not made any purchases of the company's stock. The insider transaction history for Hims & Hers Health Inc (HIMS, Financial) indicates a trend of more insider selling than buying over the past year, with 63 insider sells and no insider buys recorded.
On the date of the insider's recent sale, Hims & Hers Health Inc (HIMS, Financial) had a market capitalization of approximately $2.81 billion, with shares trading at $13.19 each.
The stock's valuation, according to the GuruFocus Value, was $12.28 per share, which suggests that Hims & Hers Health Inc (HIMS, Financial) was fairly valued with a price-to-GF-Value ratio of 1.07 at the time of the sale. The GF Value is a proprietary intrinsic value estimate from GuruFocus, which is determined by historical trading multiples, an adjustment factor based on the company's historical returns and growth, and future business performance estimates provided by Morningstar analysts.
The insider trend image above reflects the recent selling and buying activities of insiders at Hims & Hers Health Inc (HIMS, Financial).
The GF Value image provides a visual representation of the stock's current price in relation to its intrinsic value, indicating that the stock is fairly valued based on GuruFocus's analysis.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
